SEC Comment Letter 0000000000-22-013971 to BioPlus Acquisition Corp. (CIK 0001856653)
BioPlus Acquisition Corp. (CIK 0001856653)
Date: Dec. 29, 2022 · CIK: 0001856653 · Accession: 0000000000-22-013971
AI Filing Summary & Sentiment
File numbers found in text: 001-41116
Letter
United States securities and exchange commission logo December 29, 2022 Ross Haghighat Chief Executive Officer and Chief Financial Officer BioPlus Acquisition Corp. 260 Madison Avenue, Suite 800 New York, NY 10026 Re:BioPlus Acquisition Corp. Form 10-K for the year ended December 31, 2021 File No. 001-41116 Dear Ross Haghighat: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Real Estate & Construction
Show Raw Text
United States securities and exchange commission logo
December 29, 2022
Ross Haghighat
Chief Executive Officer and Chief Financial Officer
BioPlus Acquisition Corp.
260 Madison Avenue, Suite 800
New York, NY 10026
Re:BioPlus Acquisition Corp.
Form 10-K for the year ended December 31, 2021
File No. 001-41116
Dear Ross Haghighat:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Real Estate & Construction